The Experts below are selected from a list of 7980 Experts worldwide ranked by ideXlab platform
Joanna Giebułtowicz - One of the best experts on this subject based on the ideXlab platform.
-
Higher Cerebrospinal fluid to plasma Ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.
Clinica Chimica Acta, 2019Co-Authors: Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanislaw Szlufik, Dariusz Koziorowski, Joanna GiebułtowiczAbstract:Abstract Background In Parkinson’s disease (PD), impairment of brain to blood barrier and/or blood-Cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentRations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. Methods Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. Results In PD, for IS and pCS, CSF-plasma Ratio was higher. ConcentRation of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. Conclusions The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
Bartłomiej Sankowski - One of the best experts on this subject based on the ideXlab platform.
-
Higher Cerebrospinal fluid to plasma Ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.
Clinica Chimica Acta, 2019Co-Authors: Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanislaw Szlufik, Dariusz Koziorowski, Joanna GiebułtowiczAbstract:Abstract Background In Parkinson’s disease (PD), impairment of brain to blood barrier and/or blood-Cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentRations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. Methods Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. Results In PD, for IS and pCS, CSF-plasma Ratio was higher. ConcentRation of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. Conclusions The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
Karolina Księżarczyk - One of the best experts on this subject based on the ideXlab platform.
-
Higher Cerebrospinal fluid to plasma Ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.
Clinica Chimica Acta, 2019Co-Authors: Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanislaw Szlufik, Dariusz Koziorowski, Joanna GiebułtowiczAbstract:Abstract Background In Parkinson’s disease (PD), impairment of brain to blood barrier and/or blood-Cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentRations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. Methods Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. Results In PD, for IS and pCS, CSF-plasma Ratio was higher. ConcentRation of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. Conclusions The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
Emilia Raćkowska - One of the best experts on this subject based on the ideXlab platform.
-
Higher Cerebrospinal fluid to plasma Ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.
Clinica Chimica Acta, 2019Co-Authors: Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanislaw Szlufik, Dariusz Koziorowski, Joanna GiebułtowiczAbstract:Abstract Background In Parkinson’s disease (PD), impairment of brain to blood barrier and/or blood-Cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentRations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. Methods Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. Results In PD, for IS and pCS, CSF-plasma Ratio was higher. ConcentRation of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. Conclusions The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.
Stanislaw Szlufik - One of the best experts on this subject based on the ideXlab platform.
-
Higher Cerebrospinal fluid to plasma Ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson's disease.
Clinica Chimica Acta, 2019Co-Authors: Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanislaw Szlufik, Dariusz Koziorowski, Joanna GiebułtowiczAbstract:Abstract Background In Parkinson’s disease (PD), impairment of brain to blood barrier and/or blood-Cerebrospinal fluid (CSF) barrier is described. It can increase the level of uremic toxins in CSF. So far, role of these compounds in neurological disorders has not been completely understood. However, a link has been observed between chronic kidney disease and neurological disorders. We measured the concentRations of uremic toxins (i.e. indoxyl sulfate (IS), p-cresol sulfate (pCS), symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and trimethylamine N-oxide (TMAO)) in CSF and plasma, and correlated them with inflammation and oxidative stress biomarkers. Methods Plasma and CSF samples were collected from 27 volunteers (18 with PD and 9 controls). The level of toxins was determined using liquid chromatography coupled with tandem mass spectrometry. Results In PD, for IS and pCS, CSF-plasma Ratio was higher. ConcentRation of pCS in CSF was higher in PD compared to controls. TMAO level was also higher in plasma of that group. Patients with motor fluctuations had higher level of uremic toxins in CSF, but not in plasma. Conclusions The level of pCS and IS in CSF of PD is higher than expected, based on their blood level. It can influence pathogenesis and progression of PD.